EFTA00299784.pdf

09/18/2018 16:38 From: INIMINIM Woodson C. Merrell M Uebfax Page: 1/11 FAX COVER SHEET To: Jeffrey Epstein / Lesley From: Lisa Company: Company: Woodson Merrell MD PLLC Phone: Pages w/cover: 11 Fax: Date: 9/18/2018 Subject: 9-14-18 LABCORP (Partial) Lab Re Comments: EFTA00299784 09/10/2010 16:30 From: 3477565616 Woodson C. Merrell M Wehfax Page: 2/11 LabCorp Patient Report Specimen ID: 257-480 2371-0 Control ID: FSB31: 43092 EPSTEIN, JEFFREY 9E 71STST NEW YORK W 10021 Acct 31143092 Woodson Merrell 44 E67th St New York NY 10065 Phone Patient Details Specimen Details Physician Details DOB:01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRF.LL Age(y/m/d):065/07/25 Date received: 09/15/2018 Referring: Gender. M 55/t Date entered: 09/15/2018 ID: MERFtELL Patient ID: Date reported: 09/18/2018 0610 ET NPI: 1023153509 General Comments & Additional Information Total Volume: Not Provided Ordered Items CBC With Differential/Platelet Comp. Metabolic Panel (14); Urinalysis, Routine; PE+Interp(Rfx IFE),S; Lipid Panel; Iron and TIBC; Testosterone,Free+Weakly Bound; Vitamin 812 and Folate; FSH and Lit C-Reactive Protein, Cardiac; Hemoglobin Ale: Prostate-Specific Ag. Serum; TSH; Vitamin D. 26-Hydroxy; Lipoprotein (a); IGF-1; ANA vt/Reflex; Homocyst(e)ine, Plasma; ProlaCtini Thyroxine (14) Free, Direct. S: Cortlsol; DHEA-Sutfate; Estredlot Uric Acid; Phosphorus; LOH; GOT; Amylase; Ferritin, Serum; Insulin; COICIUM. Ionized, Serum: Fibrinogen Activity: Magnesium, RBC TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAE CBC With Differential/Platelet WBC 5.7 x10E3/uL 3.4 - 10.B 01 RBC 4.90 x10136/uL 4.14 - 5.80 01 Hemoglobin 14.7 g/dL 13.0 - 17.7 01 Hematocrit 42.2 % 37.5 - 51.0 01 MCV 86 fL 79 - 97 01 MCH 30.0 pg 26.6 - 33.0 01 MCHC 34.8 g/dL 31.5 - 35.7 01 RDW 14.6 t 12.3 - 15.4 01 Platelets 242 x1083/uL 150 - 379 01 Neutrophils 50 I Not Estab. 01 Lymphs 37 % Not Estab. 01 Monocytes 5 * Not Estab. 01 Eos 7 * Not Estab. 01 Basos 1 * Not Estab. 01 Neutrophils (Absolute) 2.8 x10E3/uL 1.4 - 7.0 01 Lymphs (Absolute) 2.1 x1083/uL 0.7 - 3.1 01 Monocytes(Absolute) 0.3 x1083/uL 0.1 - 0.9 01 Eos (Absolute) 0.4 x1083/uL 0.0 - 0.4 01 Baso (Absolute) 0.0 x10133/uL 0.0 - 0.2 01 Immature Granulocytes 0 * Not Estab. 01 Immature Grans (Abs) 0.0 x10E3/uL 0.0 - 0.1 01 Comp. Metabolic Panel (14) Glucose 128 High mg/dL 65 - 99 01 Sample is lipamic. This may cause spurious AST, ALT, and GIBC (if ordered). Clinical increases in TBili, DBili, correlation indicated. Rte: 68 Fasting: No Specimen received hemolyzed. Clinical correlation indicated. Date Issued: 09/1&181053 ET PRELIMINARY REPORT Tb-5decumemcontainsprivareandcorfidential , tested by state and federal law. II you have received this document in error, Meow WI Page 1 of S 121995-20113 Laboratory Corporation of Americas Holdings All Itghb Rained • Enterprise Ripon Version 100 EFTA00299785 09/10/2010 16:38 From: Woodson C. Merrell M Webfax Page: 3/11 ilagorP Patient Report Patient: EPSWN. JOFIIIY DO8:01/20/1953 Patient ID: Control ID: F5831143092 Specimen ID:257-480-2371-0 Date collected: 09/14/2018 1255 uxal TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB BUN Creatinine eGFR If NonAfricn Am eGFR If Africn Am BUN/Creatinine Ratio Sodium Potassium 4.2 mmol/L 3.5 - 5.2 01 Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and UIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. Chloride 102 mmol/L 96 - 106 Carbon Dioxide, Total 20 mmol/L 20 - 29 Calcium 9.4 Protein, Total 6.7 Albumin 4.3 Globulin, Total 2.4 A/G Ratio 1.8 Bilirubin, Total 0.3 Alkaline Phosphatase 71 AST (SCOT) The specimen was lipemic. The lipemia was cleared by ultracentrifugation before testing. However HDL, direct LDL, cholesterol and triglyceride (if ordered) were performed prior to ultracentrifugation. ALT (SGPT) 22 0.96 83 95 23 mg/dL mg/dL mL/min/1.73 mL/min/1.73 8 - 27 0.76 - 1.27 01 >59 >59 10 - 24 138 mmol/L 134 - 144 01 01 Urinalysis, Routine Urinalysis Gross Exam Specific Gravity pH Urine-Color Appearance WBC Esterase Protein Glucose Ketones Occult Blood Bilirubin Urobilinogen,Semi-Con Nitrite, Urine Microscopic Examination Microscopic follows PE+Interp(Rfx IFE),S mg/dL g/dL g/dL g/dL mg/dL IU/L 26 IU/L 37 IU/L 1.027 5.5 Yellow Clear Negative Negative Negative Negative Negative Negative 0.2 Negative if indicated. Will Follow EU/dL 01 01 8.6 - 10.2 01 6.0 - 8.5 01 3.6 - 4.8 01 1.5 - 4.5 1.2 - 2.2 0.0 - 1.2 01 39 - 117 01 0 - 40 01 0 - 44 01 01 1.005 - 1.030 01 5.0 - 7.5 01 Yellow 01 Clear 01 Negative 01 Negative/Trace 01 Negative 01 Negative 01 Negative 01 Negative 01 0.2 - 1.0 01 Negative 01 01 Date issued: 09/18/181053 Et PRELIMINARY REPORT lit dmument contains private and torelldentittl " otected by state and tedertl If you have receNed thedocument in error, oletne call Page? of 5 01995-2013 Laboratory Commotion of America* Holdings an POP Rewind Enterprise Ripon Versiort 100 EFTA00299786 09/10/2018 16:38 From: Woodson C. Merrell M Wehfax Page: 4/11 LabCorp Pattern: EPSTEVUE9FREY DOB:01/20/1953 Patient ID: Control ID: F5831143092 TESTS RESULT FLAG UNITS Lipid Panel Cholesterol, Total Triglycerides 234 2714 High Alert mg/dL mg/dL mg/dL mg/dL Results confirmed on dilution. HDL Cholesterol VLDL Cholesterol Cal 19 Low Patient Report Spedmen 10:257-480-2371.0 Date colkcted:09/I4/2018 1255 Local REFERENCE INTERVAL LAB 100 - 199 0 - 149 01 01 >39 01 5 - 40 The calculation for the VLDL cholesterol is not valid when triglyceride level is >400 mg/dL. LDL Cholesterol Cale mg/dL 0 - 99 Triglyceride result indicated is too high for an accurate LDL cholesterol estimation. Iron and TIBC Iron Bind.Cap.(TIBC) 320 UIBC 252 Iron 68 Iron Saturation 21 ug/dL 250 - 450 ug/dL 111 - 343 01 ug/dL 38 - 169 01 t 15 - 55 Testosterone, Free+Weakly Bound Testosterone, Serum 140 Low ng/dL 264 - 916 01 Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCHM 2017,102;1161-1173. PMID: 28324103. Testost., % Free+Weakly Bound Will Follow V 9.0 - 46.0 02 Testosc., F+W Bound Will Follow ng/dL 40.0 - 250.0 Vitamin B12 and Folate Will Follow FSH and LH LH FSH C-Reactive Protein, Cardiac 3.7 mIU/mL 1.7 - 8.6 01 4.4 mIU/mL 1.5 - 12.4 01 1.56 mg/L 0.00 - 3.00 01 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 Hemoglobin Alc Hemoglobin Alc 5.5 4.8 - 5.6 01 Please Note: 01 Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.7 ng/mL 0.0 - 4.0 01 Dare Issued. 09/18181053 ET PRELIMINARY REPORT The document contalm. white and corfidential beak ' recite by state and federal law. If you have rend this document into'', please call Page 3 of5 A 1995-2018 Laboratory Corporadon of ArneriCell Holdings All Rights Reserved • Enterprise Report Veniore 100 EFTA00299787 09/10/2010 16:30 From: MISIMO Woodson C. Merrell 11 Yebfax Page: 5/11 ktalbetorP Patient Report Patient: EPSIEIKJEFFREY 008:01/20/I953 Patient ID: Control ID: F5831143092 Specimen ID: 257-S80-2371D Date collected:09/14/2018 1255 Local TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB TSH Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. 1.290 uIU/mL 0.450 - 4.500 01 Vitamin D, 25-Hydroxy 20.2 Low ng/mL 30.0 - 100.0 01 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-0H vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Bolick MP, Hinkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEN. 2011 Jul; 96(7):1911-30. Lipoprotein (a) 20 nmol/L <75 Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities. IGF-1 Insulin-Like Growth Factor I 137 ng/mL 49 - 188 ANA w/Reflex ANA Direct Negative Negative Homocyst(e)ine, plasma 14.9 umol/L 0.0 - 15.0 Prolactin 3.9 Low ng/mL 4.0 - 15.2 Thyroxine (T4) Free, Direct, T4,Frce(Directi S 1.05 ng/dL 0.82 - 1.77 Cortisol 3.7 ug/dL Cortisol AM 6.2 - 19.4 Cortisol PM 2.3 - 11.9 01 02 01 01 01 01 01 Date Issueo: 09/18/18 1053 ET PRELIMINARY REPORT Pape 4 of 5 This document contains private and confidereiel health information otected by state and federa Haw. If you hive received this6000mm in error, Please 19952018 Liboratory Corporation of America* Hoklings NI Rights Reserved -Enterprise Report Pollen: 1,00 EFTA00299788 09/18/2818 16:38 From: Woodson C. Merrell M Uebfax Page: 6/11 :l-LabCorp Patient Report Patient: EPSTEIN, JEFFREY D09:0120/1953 Patient ID: Control ID: F5831143092 Specimen ID: 2574804371-0 Date collected: 09/14/2018 1255 L0 GI TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB DENA-Sulfate Estradiol Roche ECLIA methodology Uric Acid Uric Acid Please Note: 181.8 ug/dL 30.9 - 295.6 01 28.3 pg/mL 7.6 - 42.6 01 6.8 mg/dL 3.7 - 8.6 01 01 Therapeutic target for gout patients: <6.0 Phosphorus 3.6 mg/dL 2.5 - 4.5 01 LDH 213 IU/L 121 - 224 01 GGT 25 IU/L 0 - 65 01 Amylase 37 U/L 31 - 124 01 Ferritin, Serum Will Follow Insulin 47.2 High uIU/mL 2.6 - 24.9 01 Calcium, Ionised, Serum 5.3 mg/dL 4.5 - 5.6 01 Fibrinogen Activity 330 193 - 507 01 Specimen was ultracentrifuged before testing to remove extreme lipemia. Results should be interpreted with caution. Magnesium, RBC 5.4 mg/dL 4.2 - 6.8 02 Plasma NOT separated from cells; may falsely decrease RBC Magnesium levels. 01 RN LabCorp Raritan 69 First Avenue. Raritan, NJ 08889-1800 02 BN LabCorp Burlington 1447 York Court. Burlington, NC 27215-3361 For inquiries, the phys'cian may contact Branch: 800431-5250 Lab: Dir. Aracei B Reyes. MD DO: Wham F Hancock, MD Date ISSued: 09/18/18 1053 ET PRELIMINARY REPORT Wsdocument contains pnvate and confidential health informadon tected by state and federal law. it you have welved thisdocument enrol, *Me cal Page s as 01995-2018 Laboratory Corporaoa of Arnericae Holdings RiphiAntrad • purpose ReportVaniort 1.00 EFTA00299789 09/10/2018 16:30 From: eilleklin Woodson C. Merrell M Webfax Page: 7/11 NLabCon) Patient Report Specimen ID: 257.480.22320 Control ID: FSA31143092 EPSTEIN, JEFFREY PatientDetails 1208:01/20/1953 Agefy/rn/d): 065/07/25 Gender. M SSW Patient Kr Acct I: 31143092 Woodson Merrell 44 E 67th St New York NY 10065 Specimen Details Date collected: 09/14/2018 1255 Local Date receive* 09/15/2018 Date entered: 09/15/2018 Date reports: 09/16/2018 0808 ET General Comments & Additional Information Total Volume: Not Provided Ordered Items Ca+PTH Intact Fasting: No Phone: Physician Details Ordering: Referring: ID: MERRELL NPI: Rte: 68 TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAE Ca+PTH Intact Calcium 9.5 mg/dL 8.6 - 10.2 Specimen received hemolyzed. Clinical correlation indicated. 01 PTH, Intact 71 High pg/ML 15 65 01 Intact PTH 01 Interpretation Intact PTH Calcium (pg/mL) (mg/dL) Normal 15 - 65 8.6 - 10.2 Primary Hyperparathyroidism >65 >10.2 Secondary Hyperparathyroidism >65 <10.2 Non-Parathyroid Hypercalcemia <65 >10.2 Hypoparathyroidism <15 < 8.6 Non-Parathyroid Hypocalcemia 15 - 65 < 8.6 01 RN LabCorp Raritan 69 First Avenue Raritan NJ 08889-1800 Dir. Aracei B Reyes, MD Fee Inquiries, the physician may canted Branch: Lab: Welssued:0WIN180916U FINAL REPORT This docurront corcalre private and confidential health' hived by state and federal law. if wau have receiveo this document in error, please call Page I of 1 O1995.2018 Laboratory Corporation of Americas Holdings All lights Reserved • Fnterprhe Report Venlow 140 EFTA00299790 09/18/2018 16:30 From: Woodson C. Merrel l M Uebf ax Page: 8/11 ILaltorp Patient Report Specimen ID: 257-480.2715-0 Control a END31143092 EPSTEIN, JEFFREY 9E 715TST NEWYORK NY 10021 Patient Details DOB: 01 /20/1953 Age(y/m1d): 065/07/25 Gender: M SSN: Patient ID: Acct 1:31143092 Phone: Rte 68 Woodson Merrell 4-1E 67th St New York NY 10065 tRrlhlheduPPhrddUllhhrnhrlllrllllllllhIdnlhll Specimen Details Date collected: 09/14/2018 1255 Local Date received: 09/15/2018 Date entered: 09/15/2018 Date reported: 09/18/2018 0610 ET Physician Details Ordering: W MERRELL Referring: ID: NPt 1023153509 General Comments & Additional Information Total Volume: Not Provided Ordered Items Chlamydie/GC Amplificason, Panel 083935; HCV Ab w/Rflx to Verification; RPR, Rfx On RPR/Confirm TP Fasting: No TESTS RESULT FLAG LWITS REFERENCE INTERVAL LAE Chlemydia/GC Amplification Chlamydia trachomatis, NAA Neisseria gonorrhoeae, NAA Negative Negative Panel 083935 HIV Screen 4th Generation wRfx Non Reactive Negative Negative 01 01 Non Reactive 01 HCV Lb w/Rflx to Verification HCV Ab c0.1 s/co ratio 0.0 - 0.9 01 Comment: 01 Non reactive HCV antibody screen is consistent with no HCV infection, unless recent infection is suspected or other evidence exists to indicate HCV infection. RPR, Rfx Qn APR/Confirm TP RPR Non Reactive Non Reactive 01 01 RN LabCorp Raritan 6$ First Avenue. Etonian, NJ 08869-1800 for equines. the physician may contact Branch: Lab: Dir: Aracek B Reyes. MD Date 'snitch:M/18M 1053 Er FINAL REPORT This document contains private and confidential health information tested by state and federal law. It you here receivedthis docurmot in emb *me tali Pagel& 1 01995.2018 Laboratory Corr/oleo of America. Flokengs M RightsReeved-Enterprise Reran Version: 1O0 EFTA00299791 09/10/Z018 16:30 From: Woodson C. Merrel l 11 Uebfax Page: 9/11 Patient Report Specimen 10: 257-480-25424 Control ID: F5C31143092 EPSTEIN, JEFFREY 9E 715T ST NEW YORK NY 10021 Patient Details DOB:01/20/1953 Age(y/m/d): 065/07/25 Gender: M SSN: Patient ID: Acct 31143092 Woodson Merrell 44 E 67th St New York NY 10065 Phone: Rte•. 68 Specimen Details Physician Details Date collected: 09/14/2018 1255 Local Ord:witty W MERRELL Date received: 09/15/2018 Refining: Date entered: 09/15/2018 ID: MERRELL Date reported: 09/10/2018 082,3 ET Nit 1023153509 General Comments & Additional Information Total Volume: Not Provided Ordered Items Zinc. Whole Blood Fasting: No TESTS RESULT FLAG UNITS DEFERENCE :UTERI/AL LAB Zinc, Whole Blood 749 r 01 BN LabCorp Burlington 1447 York Court. Burlington, NC 27215-3381 ug/dL 440 - 860 01 For inquiries. the physician may contact Branch: Lab: Mr Wi11em F Hancock MO Date Issued 09/1snelos3 ET FINAL REPORT This docament omelets private and confideraier health InformatOrt tected by state and federal bw. If you have feCifved this document in el for, please cell Page 1 or 1 0 1995.2O18 Laboratory Corporation of Afne*ae Holdings Ali Rights Reserved - Interprife Repoli Vetvorr 1.00 EFTA00299792 09/10/2018 16:38 From: Woodson C. Merrell M Webfax Page: 10/11 'ILabCorp Specimen ID: 25/-480-23000 Control ID: 25648023000 Patient Report EPSTEIN, JEFFREY 9 EAST 71 STREET NYC NY 10021 Patient Details DOB:01/20/1953 Age(y/m/d): 065/07/25 Gender: M SSN: Patient ID: Acct a: 31143092 Phone Rte: 68 Woodson Merrell 44 E 67th St New York NY 10065 qvillIrdurP444HdPIN400WPIPIQudel Specimen Details Date collected: 09/14/2018 1255 Local Date received: 09/15/2018 Date entered: 09/15/2018 Date reported: 09/17/2018 2010 ET Physician Details Ordering: W MERRELL Referring: ID: MERRELL NPI: 1023153509 Ordered Items Heavy Metals Profile II, Blood TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Heavy Metals Profile II, Blood Lead, Blood Will Follow Blood Lead Collection Method: Venous Testing performed by Inductively coupled ug/dL 0 - 4 plasma/Mass Spectrometry. Environmental Exposure: WHO Recommendation <20 01 Occupational Exposure: OSHA Lead Std 40 BEI 30 Detection Limit is 1 Arsenic, Blood 8 ug/L 2 - 23 01 Detection Limit = 1 Mercury, Blood 2.1 ug/L 0.0 - 14.9 01 Environmental Exposure: <15.0 Occupational Exposure: BEI - Inorganic Mercury: 15.0 Detection Limit a 1.0 Cadmium, Blood None Detected ug/L 0.0 - 1.2 01 Environmental Exposure: Nonsmokers 0.3 - 1.2 Smokers 0.6 - 3.9 Occupational Exposure: OSHA Cadmium Std 5.0 BEI 5.0 Detection Limit a 0.5 01 BN LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361 For Inquiries. to physician may contact Branch: Lab: Dir: Wham F Hancock, MD Date Issued: 05/18118 1053 ET PRELIMINARY REPORT This document contains private endconfidential heath inftwnstuian ted by state am fedetel kw. It you have waived this docurrant error, please cal Page 1 of 0 1015-2018 Laboratory Corporation of Amencee Holdings AI Rights Reserved • Entemtlw Report Venton: 100 EFTA00299793 09/18/2818 16:38 From: orn:l Mt.00 l% 44-7e I Woodson C. Merrell n Meninx rage: 00/17/2010 21:02 0442 GM /007 I M UGE N. Reference Diagnostic Division Oxford Immunotec, Inc. cVb/a IMUGEN 316 Norwood Park South. Norwood MA 02062 • • FAX Submkten Lyme Antibody Analysis Patient: WOODSON C MERRELL MD Name: JEFFREY EPSTEIN SUITE IB Address: 9 EAST 71ST STREET 44 EAST 67TH STREET NEW YORK NY 10021 NEW YORK NY 10066 D.O.B.: 0020/1953 Order rg Submitter Provide:: WOCDSON C MERRELL MD Record #: IMUGEN Account #: MERW Patient #: 2018013061 Antibody Capture Enzyme Immunoassay Test Date: 0W17/2018 Antigen Antibody 880e/P41 Results PLASMA 6 13061 Coned, owe. C011Y2018 Olecoct PM COMIOU CSP 6 0:00m Dean Riteipi nee B. burgdoeferi 49736 IIIM <1 IgG <1 IfIA <I Wires felted the terathie amount of B burpotriermarre#4# mai* #0#444.4 br lanckirrtinil Normal Range: no rmcdy detected et <0.8 for IgM and <1 for IgG and lgA. Comments: No IgM. IgG or IgA antibody to B. burgdorferi detected by cabbie Elk the IgG immunoblot results tel within normal limits. Interpretation: No serologic evidence of infection with 8. burgdorferi (Lyme). Immunoblot IgG (Western Blot) PLASMA /* 1306 Test Date: 0W17/2018 8. bsrgctorlert639/40 58 II Reactive bands la Eat m dD d 8. 0urgdorton antigens nth Mich IgG is reactive. Norval Range: Reactivity to <5 antigens on each blot 8. burrkrksi 49736 SS 41 Mabli aural yanliaorlanal SU, orl CA prooalaneldcar modal a Savo lao 1: aativ• noull dW no, 0e Illoccablhcdlaictla. a ilea • wales abate mar nel Miw PRIWA O. Pop Imo al Mood earroa wham of ea a yao *Rao& 3;• tin MU' LAA SM faults Amp*. n • entle00101 0200 WC tie COWS Mks KItry Wench euggeen Hear. ore awalasn ea Iola unaer Pair reap nalol Nast Oaeltemearibc0 wave tears on:taw snasur .enrina.ind %ass • Int rut WINN Mast sot to grata aka Minootlaloo alA carmad Oa% Pilrlaa a. a La tact m ft sae F.Ot a Nolo $: mew es< Awe *maw Ana to Dallara Canova der**. Et Planet 0<7 hsnw tees *On e 01 OOPevea Ws, Mk M rabaloll It "O/Se ner WA al Uloalm aka hicaoaary boa Pia acth ants anew. Y toy *cum a be Lnprthid w lonaanis Cad lima, NOY ll: A yak.• ma env no oadi. to pommy or • encomia:innand paw aclice. 'Mee P10 MID. Ph D. Director the AMEN bgo is a regateral trademark i24 Oxford immunAtc. o 2o17 Mere froneraec. Report Dade: owimola KEV//JAL CLIA number 2200850196 EFTA00299794